首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1562329

欧洲人疫苗佐剂市场预测至 2030 年 - 区域分析 - 按类型、应用（流感、肝炎、人类乳突病毒等）和最终用户

Europe Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), and End User

出版日期: 2024年07月04日 | 出版商:

The Insight Partners | 英文 113 Pages | 订单完成后即时交付

价格

简介目录图表

2022年欧洲人用疫苗佐剂市场价值为47233万美元，预计2030年将达到133800万美元；预计2022年至2030年复合年增长率为13.9%。

个人化疫苗的崛起推动欧洲人用疫苗佐剂市场

精准或个人化疫苗是欧洲人疫苗佐剂市场的成长趋势。这些疫苗针对患者疾病的特定遗传或分子特征，有助于生产适合每位患者独特免疫反应的疫苗。该技术可以潜在地提高疫苗接种的功效和安全性，从而增加人们对治疗癌症、传染病和自体免疫疾病等疾病的个人化疫苗的兴趣。

生产个人化疫苗需要能够增强对这些客製化疫苗的免疫反应的佐剂。佐剂对于刺激免疫系统对疫苗的特定抗原产生有针对性的强大反应至关重要。因此，对能够有效增强个人化疫苗免疫反应的佐剂的需求不断增加。近年来，人们非常重视研发工作，以确定并创造能够有效增强个人化疫苗免疫反应的佐剂。例如，2022 年 12 月，Moderna 和默克宣布推出 mRNA-4157/V940，这是一种在研个人化 mRNA 癌症疫苗，与 KEYTRUDA(R)（pembrolizumab）联合使用。与单独使用 KEYTRUDA 相比，mRNA-4157/V940 合併 KEYTRUDA 辅助治疗可将復发或死亡风险降低 44%。监管机构和医疗保健组织认识到个人化疫苗在改善公共卫生结果方面的潜力。例如，2023 年1 月，BioNTech 和英国政府签署了一份影响广泛的谅解备忘录(MoU)，到2030 年为多达10,000 名患者提供个人化mRNA 癌症免疫疗法。的资金，加快个人化疫苗和佐剂监管途径的措施。因此，越来越多地开发有效改善个体化疫苗接种的免疫反应的佐剂，从而提高疫苗的功效和安全性。这一趋势推动了欧洲人类疫苗佐剂市场的大量创新和投资。

欧洲人用疫苗佐剂市场概况

德国是欧洲乃至全球最大的医药市场之一。据德国贸易投资总署 (GTAI) 称，它是欧盟最大的药品生产基地，拥有约 600 家製药公司。根据GTAI 的数据，到2022 年，德国的药品产量将达到约618 亿美元（约565 亿）。基础设施、持续成长的当地化学工业，以及高素质的劳动力可用性。同一消息人士称，2021年德国製药业研发投资近95亿美元（约88亿美元），高于其他产业的研发投资金额。德国的医疗保健产业迎合了欧洲最多的人口，是一个极具吸引力的市场，具有巨大的成长机会。预期寿命水准的稳定增长导致慢性病和与年龄相关的疾病的增加。传染病流行率的增加预计将刺激疫苗接种的需求。例如，根据 ICO/IARC 资讯中心 2023 年 HPV 与癌症报告，德国有 3,660 万名 15 岁及以上女性面临 HPV 相关子宫颈癌的风险。此外，德国的肝炎盛行率很高。由于传染病的流行，健康意识的提高进一步增加了消费者对药物、疫苗和疗法的需求。因此，随着製药公司医药研发领域的蓬勃发展以及传染患者病率的不断上升，德国对人用疫苗佐剂的需求正在迅速增长。

欧洲人类疫苗佐剂市场收入及 2030 年预测（百万美元）

欧洲人用疫苗佐剂市场区隔

欧洲人疫苗佐剂市场按类型、应用、最终用户和国家分类。

根据类型，欧洲人疫苗佐剂市场分为颗粒佐剂、乳液佐剂、组合佐剂等。 2022 年，颗粒助剂领域占最大的市场份额。

从应用来看，欧洲人用疫苗佐剂市场分为流感、肝炎、人类乳突病毒（HPV）等。 2022 年，流感细分市场占据最大市场。

依最终用户划分，欧洲人疫苗佐剂市场分为製药和生技公司、CMO 和 CRO 等。 2022 年，製药和生物技术公司细分市场占据最大市场份额。

依国家划分，欧洲人疫苗佐剂市场分为德国、英国、法国、义大利、西班牙和欧洲其他国家。 2022年，德国在欧洲人用疫苗佐剂市场占有率中占据主导地位。

Creative Biolabs Inc、Croda International Plc、CSL Ltd、Dynavax Technologies Corp、Novartis AG、Novavax Inc、Phibro Animal Health Corp、Seppic SA 和 SPI Pharma Inc 是欧洲人类疫苗佐剂市场上的一些领先公司。

Precision or personalized vaccines are a growing trend in the Europe human vaccine adjuvants market. These vaccines target specific genetic or molecular characteristics of a patient's disease, assisting the production of vaccines tailored to each patient's unique immune response. The technique can potentially improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders.

Adjuvants that can boost the immune response to these tailored vaccines are required to produce personalized vaccines. Adjuvants are essential in stimulating the immune system to develop a targeted and powerful response to the vaccine's specific antigens. As a result, there is an increasing demand for adjuvants that can effectively boost immune responses to personalized vaccines. In recent years, there has been a strong emphasis on R&D efforts to identify and create adjuvants that can effectively increase the immune response to personalized vaccines. For instance, in December 2022, Moderna and Merck announced mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab). Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared with KEYTRUDA alone. Regulatory bodies and healthcare organizations recognize personalized vaccines' potential for enhancing public health outcomes. For instance, in January 2023, BioNTech and the UK government signed a wide-reaching Memorandum of Understanding (MoU) to provide up to 10,000 patients with personalized mRNA cancer immunotherapies by 2030. This has increased funding for research and development initiatives in this field and measures to expedite regulatory routes for personalized vaccines and adjuvants. Thus, adjuvants that effectively improve the immune response to personalized vaccinations are increasingly being developed, enhancing vaccine efficacy and safety. This trend drives substantial innovation and investment in the Europe human vaccine adjuvants market.

Europe Human Vaccine Adjuvants Market Overview

Germany is one of the top pharmaceutical markets in Europe and worldwide. According to Germany Trade & Invest (GTAI), it is the biggest pharmaceutical manufacturing location in the European Union, with approximately 600 pharmaceutical companies. According to GTAI, pharmaceutical production volume in Germany reached ~US$ 61.8 billion (~ 56.5 billion) in 2022. Further, the country ranks second in biopharmaceutical production after the US, which is attributed to favorable industrial infrastructure, a sustainably growing local chemicals industry, and highly qualified workforce availability. According to the same source, the pharmaceutical industry in Germany invested almost US$ 9.5 billion (~ 8.8 billion) in R&D in 2021, which is higher than the amounts invested in the R&D of any other industry. Catering to the largest population in Europe, Germany's healthcare sector is a highly attractive market with significant growth opportunities. A steady increase in life expectancy levels has led to a rise in chronic and age-related illnesses. An increase in the prevalence of infectious diseases is expected to fuel the demand for vaccinations. For instance, according to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, Germany has a population of 36.6 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Additionally, Germany has a high prevalence of hepatitis. Improved health awareness due to the prevalence of infectious diseases has further increased consumer demand for drugs, vaccines, and therapies. Thus, the demand for human vaccine adjuvants is growing rapidly in Germany with the flourishing pharmaceutical R&D landscape in pharmaceutical companies, alongside the increasing prevalence of infectious diseases.

Europe Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Europe Human Vaccine Adjuvants Market Segmentation

The Europe human vaccine adjuvants market is categorized into type, application, end user, and country.

Based on type, the Europe human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.

In terms of application, the Europe human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.

By end user, the Europe human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.

By country, the Europe human vaccine adjuvants market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe human vaccine adjuvants market share in 2022.

Creative Biolabs Inc, Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA, and SPI Pharma Inc are some of the leading companies operating in the Europe human vaccine adjuvants market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Human Vaccine Adjuvants Market - Key Market Dynamics

4.1 Europe Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Chronic Diseases
- 4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
- 4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
- 4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
- 4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:

5. Human Vaccine Adjuvants Market - Europe Market Analysis

5.1 Europe Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 Europe Human Vaccine Adjuvants Market Forecast Analysis

6. Europe Human Vaccine Adjuvants Market Analysis - by Type

6.1 Particulate Adjuvant
- 6.1.1 Overview
- 6.1.2 Particulate Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
- 6.2.1 Overview
- 6.2.2 Emulsion Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
- 6.3.1 Overview
- 6.3.2 Combination Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
- 6.4.1 Overview
- 6.4.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Human Vaccine Adjuvants Market Analysis - by Application

7.1 Influenza
- 7.1.1 Overview
- 7.1.2 Influenza: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
- 7.2.1 Overview
- 7.2.2 Hepatitis: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human Papilloma Virus (HPV)
- 7.3.1 Overview
- 7.3.2 Human Papilloma Virus (HPV): Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Human Vaccine Adjuvants Market Analysis - by End User

8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Overview
- 8.1.2 Pharmaceutical and Biotechnology Companies: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
- 8.2.1 Overview
- 8.2.2 CMOs and CROs: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Human Vaccine Adjuvants Market - Country Analysis

9.1 Europe
- 9.1.1 Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  - 9.1.1.1 Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 Germany Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.1.2 Germany Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.1.3 Germany Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.2 UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 UK Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.2.2 UK Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.2.3 UK Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.3 France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 France Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.3.2 France Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.3.3 France Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.4 Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.1 Italy Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.4.2 Italy Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.4.3 Italy Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.5 Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.5.1 Spain Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.5.2 Spain Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.5.3 Spain Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.6 Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.6.1 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.6.2 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.6.3 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by End User

10. Industry Landscape

10.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Dynavax Technologies Corp
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 CSL Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Seppic SA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 SPI Pharma Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Croda International Plc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Novavax Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Phibro Animal Health Corp
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Creative Biolabs Inc
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. Europe Human Vaccine Adjuvants Market Segmentation
Table 2. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 4. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 5. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
Table 6. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 7. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 8. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 9. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 10. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 11. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 12. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 13. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 14. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 15. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 16. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 17. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 18. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 19. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 20. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 21. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 23. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 24. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 25. Glossary of Terms, Human Vaccine Adjuvants Market

List Of Figures

Figure 1. Europe Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Europe Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
Figure 4. Europe Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
Figure 10. Influenza: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human papilloma virus (HPV): Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Europe Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 19. Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 21. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 22. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 23. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 24. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 25. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)